The US has seen a record 323 drug shortages in the first quarter of 2024.

The drug supply deficit has been steady since 2021, with all drug classes vulnerable to shortages, particularly sterile injectables, cancer chemotherapy, and emergency drugs.

32 chemotherapy drugs are in short supply, and the five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, and intravenous fluids.

Most treatment shortages have lasted over two years, affecting over half a million patients, mostly elderly.

Manufacturing and quality problems are often the root cause of drug shortages, with the FDA blaming manufacturing issues, supply chain gaps, and downtime for drug shortages.

The COVID-19 pandemic has worsened global supply chain problems, with export controls on medical supplies and medicines implemented in 86 jurisdictions, totaling 157 controls, in the pandemic's first six months.

Vaccine nationalism has hindered global immunization and fueled the development of more dangerous COVID-19 variants, while demand surges have disrupted global supply chains.

In France, 44% of people had faced a drug shortage, causing patient anxiety and worsening symptoms, with French health organisations blaming pharmaceutical companies' lack of transparency for rising drug prices.

The FDA declared a nationwide Adderall shortage in 2022 due to manufacturing delays, and manufacturing delays and labor shortages are contributing to the Adderall shortage.

15 cancer drugs are in short supply due to manufacturing and supply chain issues, impacting cancer care locally and nationwide.

A survey by the American Society of Health System Pharmacists found that one-third of 1,100 hospitals had to alter prescriptions due to drug shortages.

US pharmaceutical companies rely on foreign suppliers like China, India, and Italy for raw materials, making supply prone to fluctuations.

Medication shortages can lead to threats to patient safety, economic implications, an

The US has seen a record 323 drug shortages in the first quarter of 2024.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
An Unexpected Catastrophe in the World ’ s Largest Country: The Complete Story of U.S. Drug Shortages
The deficit is at a record level.
According to data from the American Society of Health System Pharmacists and the University of Utah Drug Information Service, organizations began tracking drug shortages for the first time in 2001. Steady since 2021 – now reaching a record high of 323 drugs in the first three months of 2024.
Paul Abramowitz, CEO of the American Society of Health System Pharmacists, wrote in a blog post on Thursday: “It ’ s been a long time to end drug shortages, ” and wrote:“ All drug classes are vulnerable to shortages, some of the most worrisome shortages include sterile injectable generic drugs, including cancer chemotherapy drugs and emergency drugs stored in hospital vans and procedural areas. It is dangerous for doctors and patients. ”
In addition to the 32 chemotherapy drugs that are deficient, the five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, and intravenous fluids. [1] The Drug Deficiency Database maintained by the American Society of Health System Pharmacists and the University of Utah is based on voluntary reports from practitioners, patients, and others that have been confirmed by manufacturers. The U.S. drug is in short supply, because it captures broader effects on service providers and patients.
The crisis has lasted a year and a half.
More than half of the treatment shortages have lasted for more than two years, according to an analysis by health consultancy IQVIA, and the average shortage affects at least half a million patients, many of them elderly, according to the US Office of Health and Human Services under the Assistant Secretary for Planning and Evaluation, which shared its analysis with Congress in May.
Growing demand can play a role in drug shortages, as with the recent shortage of weight-loss drugs, but often manufacturing and quality problems, such as supply chain gaps and downtime, are the root cause. And varied.
But the American Society of Health System Pharmacists has “serious concerns ” about parts of this proposal, especially financial sanctions imposed on hospitals that lack the resources to comply with the recommendations, Abramowitz wrote:“ We all know that managing shortages is not enough and is not a sustainable solution to the worsening crisis, and there is still a lot of work to be done at the federal level to fix the root causes of drug shortages. ”
Why Shortage Occurs
Shortages can be caused by high demand, as with the recent shortage of weight-loss drugs, but this is not usually the main problem.
The FDA also blames manufacturing and quality problems, supply chain gaps, and downtime, and Dr. Emily Tucker, a drug shortage expert and an assistant professor of industrial engineering at Clemson University, says that when there is an indication of shortages, large health systems often also proactively place large orders, adding to the system ’ s stress.
“I don ’ t blame anyone.
“When I talk to all the stakeholders – whether it ’ s wholesalers, manufacturers, or the government – everyone wants this problem to end, ” she said.
Lack of transparency
Dr. Julie Grallo, chief medical officer and executive vice president of the American Society of Clinical Oncology, told the House Committee earlier that the shortage puts providers in a terrible position: “The drug shortage crisis is forcing providers to make impossible choices, and it is also hindering the development of new drugs. Health drugs are purchased only on a price basis, and manufacturers do not have to disclose the source of their acquisition of the ingredients.
The shortage of this generic chemical drug came due to the closure of one factory in India that manufactures the active ingredient after a surprise FDA inspection found “significant quality issues, ” says Jarallo:“ We didn ’ t know, and there was no transparency regarding the company ’ s supply of the majority of active pharmaceutical ingredients to all manufacturers across the board.
Knowing this in advance, we could have responded much faster, ” Dr. Steven Schundlemeyer, director of the PRIME Institute of the University of Minnesota School of Pharmacy, which focuses on economic and management issues, told the committee that as with defense contractors in the United States, New Zealand requires manufacturers to disclose their suppliers, and that information is required.
Easily accessible in the database.
Related Topics

The drug supply deficit has been steady since 2021, with all drug classes vulnerable to shortages, particularly sterile injectables, cancer chemotherapy, and emergency drugs.

32 chemotherapy drugs are in short supply, and the five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, and intravenous fluids.

Most treatment shortages have lasted over two years, affecting over half a million patients, mostly elderly.

Manufacturing and quality problems are often the root cause of drug shortages, with the FDA blaming manufacturing issues, supply chain gaps, and downtime for drug shortages.

The COVID-19 pandemic has worsened global supply chain problems, with export controls on medical supplies and medicines implemented in 86 jurisdictions, totaling 157 controls, in the pandemic's first six months.

Title:

Content: Protectionism

Where's My Stuff?

Supply chains are struggling, but they're not as fragile as you think.

|

Americans can be forgiven for thinking that every critical system we rely on is breaking down. The country—nay, the globe—has endured years of social, political, environmental, and epidemiological upheaval. Pick your shock: COVID-19, wildfires, George Floyd protests, climate change, January 6. They all seem like harbingers of a chaotic future.

But backlogs in Pottery Barn orders are when shit gets real.

From Bosch dishwashers to bucatini to chicken wings to pipette tips, the past year has seen a raft of press coverage about delays, price spikes, and other disruptions to the production and shipment of goods to the United States. Strains in the global supply chain caused semiconductor shortages and big price increases for used cars. Toyota, Ford, and General Motors have all scaled back production in recent months because of the dearth of computer chips. When the container ship Ever Given temporarily ran aground in the Suez Canal, the Financial Times asserted that the accident showed "the inherent fragility of tightly stretched global supply chains at the very moment when they are already being buffeted by a pandemic and in an era when the philosophical underpinnings of global trade are being challenged."

Journalists aren't the only folks freaking out. Less than six weeks into his term, President Joe Biden issued an executive order mandating that eight cabinet departments examine the resilience of U.S. supply chains, warning that "pandemics and other biological threats, cyber-attacks, climate shocks and extreme weather events, terrorist attacks, geopolitical and economic competition, and other conditions can reduce critical manufacturing capacity and the availability and integrity of critical goods, products, and services." More recently, Biden has floated multiple policy responses, including using the National Guard to untangle snarled supply chains.

The administration's concern about global supply chains fits in with the political elite's larger ideological pivot away from trade liberalization and toward a more mercantilist posture. Indeed, this is the area where the Biden and Trump administrations sound the most similar. Biden's U.S. trade representative, Katherine Tai, stated in a congressional hearing that trade liberalization and tariff reductions were no longer her office's principal goals. In June, Biden's National Economic Council director, Brian Deese, declared that "resilient supply chains must be at the center of a 21st century industrial strategy." One of Biden's senior directors at the National Security Council has told me that "the U.S. is not a trade-dependent nation." Another administration official questioned to me whether the notion of comparative advantage in trade still exists. Never one to be outdone in policy freakouts, Sen. Josh Hawley (R–Mo.) has introduced a bill requiring more than half the value-added of any critical good to be domestically sourced.

The recent convulsions in global supply chains do highlight ways the globalization of the past decade differs from the idealized models taught in introductory economics courses. Globalization has produced far more market concentration than would have been expected a generation ago. The tripling of the Baltic Dry Index (which measures the cost of shipping dry goods such as coal or steel between ports) and the quintupling of U.S.-China container shipping rates over the past year demonstrate that frictionless markets do not exist. Rising geopolitical tensions between the United States and China reveal the ways that great power competition will complicate cross-border exchange. And the pandemic showed how the global economy can be buffeted by shocks that textbooks typically do not discuss.

A closer look at global value chains reveals ways that both public-sector and private-sector actors have prioritized short-term efficiency at the expense of long-term resilience. But it also reveals a mismatch between a lot of overheated political rhetoric and an actual understanding of how the global economy works. Many of the past year's issues are temporary—and when it comes to strained global supply chains, globalization is more often the solution than the problem.

When Ford completed its massive River Rouge plant in 1928, it created a factory that controlled every facet of car production, including its own steel mill. Trade volume was high during this era, but very few intermediate goods crossed borders. In the time since then, the industrial organization of production has changed a wee bit.

Whereas trade a century ago was primarily in finished goods, manufacturing now has disaggregated itself into myriad chains of subcontractors. As one MIT Sloan Management Review article summarized the phenomenon, we have a "deeper tiering of supply chains whereby suppliers draw upon their suppliers who in turn draw on their own networks of suppliers in multistage production networks."

Why did this happen? The end of the Cold War eliminated most geopolitical concerns about where to locate production facilities. Basic trade theory meant an awful lot of facilities expanded in China, the low-cost manufacturing locale. The reduction of transportation and communication costs made it easier for production to be disaggregated and managed at a distance. "Just-in-time" manufacturing encouraged companies to hold minimal inventories and count on suppliers to respond quickly to fluctuations in consumer demand. Management consultants stressed the efficiency of offshore outsourcing.

The most widely cited example of the globalized supply chain is Apple's iPhone. Most people know that the iPhone is manufactured in China and exported to the United States. What is less well known is that China plays only a minor role in the creation of its added value. The iPhone's flash drive comes from the Japanese firm Toshiba. Samsung, a South Korean firm, provides the application processor. A German company provides the camera module, and a U.S. subcontractor provides the Bluetooth application. All of these parts are then assembled by a Taiwanese firm, Foxconn, with operations in Shenzhen, China.

The management consultants were right about the efficiency. While productivity in the service sector stagnated after the turn of the century, manufacturing productivity continued to soar.

The political economy advantages were also apparent after the collapse of Lehman Brothers. The last time a financial shock of that magnitude hit, the trade wars of the Great Depression began. 2008 was different. A World Bank study examined trade restrictions immediately after 2008 and found that "vertical specialization" was the most powerful economic factor that limited tariff increases. The more a country's economy was enmeshed in global supply chains, the less likely it was to raise barriers to trade. Global supply chains help explain why the Great Recession did not lead to trade wars like those of the Great Depression.

So these global value chains seemed like an unalloyed good. And then the 2010s happened.

As global supply chains grew more and more complex, there were signs of trouble on the horizon. In 2011, the Chao Phraya River floods in Thailand severely but temporarily constricted production of hard disk drives, because close to half of global output was sourced from Thailand. In 2017, U.S. hospitals faced an acute shortage of IV bags after Hurricane Maria knocked out a key production facility in Puerto Rico.

The 2011 earthquake and tsunami that hit Fukushima in Japan affected key nodes in global manufacturing. Some firms suspended sales of cars in certain colors because key ingredients were stored near Fukushima and inaccessible. An iPhone designer warned The New York Times that "there are all kinds of little specialized parts without second sources, like connectors, speakers, microphones, batteries and sensors that don't get the love they deserve. Many are from Japan."

These supply chain hiccups highlighted one underanticipated phenomenon of globalization: Rather than strengthen market competition, it strengthened market concentration. Consumer-facing firms from Walmart to Ford to Apple to Home Depot stressed cost minimization ubër alles. Firms that excelled at efficiently producing one part became near-monopolists for that component. This is how Taiwan Semiconductor Manufacturing Company (TSMC) became the dominant global supplier of customized semiconductor chips. Other chipmakers focused on design, subcontracting to the Taiwanese firm for the physical production. As TSMC accrued comparative advantages in chip production, even established competitors such as Intel struggled.

The return of geopolitical competition has also flummoxed producers. China is a critical node in almost every global value chain. Over the last decade, as Xi Jinping has consolidated his power, the Chinese state has taken a number of steps that have raised hackles in Western capitals. Some of these, such as the Belt and Road Initiative, have been overhyped. Others, such as the subjugation of the Uyghurs, repression in Hong Kong, increasing control over United Nations agencies, and the expansion of China's nuclear arsenal, have not. Xi's "wolf warrior diplomacy" has triggered evaluations in the United States, Europe, and Pacific Rim about just how vulnerable their economies are to disruptions from Chinese suppliers. The 2010 rare earth embargo on Japan in response to a territorial dispute in the East China Sea offered a warning about how China could weaponize the interdependence of global value chains; Huawei's dominance in 5G offered another. Erratic U.S. policies during the Trump administration served in turn as a warning about how Western governments could disrupt global value chains.

Finally, the COVID-19 pandemic exacerbated the problems of both market concentration and political whimsy. As China reeled from the pandemic's first wave, there were disruptions across the global economy. China exercised state power to seize domestically produced personal protective equipment and other medical supplies; the United States soon reciprocated. According to Global Trade Alert, 157 export controls on medical supplies and medicines were put in place across 86 jurisdictions in the first six months of the pandemic. U.S. leaders expressed concerns about vulnerability to China weaponizing its role in medical supply chains. So did journalists: In May 2021, 60 Minutes warned that "COVID showed that the global supply chain of chips is fragile." The Washington Post concurred: "The pandemic has exposed fragile global supply chains across multiple continents."

Countries exercised vaccine nationalism, stunting global immunization against COVID-19, which in turn facilitated the development of more dangerous variants of the novel coronavirus. The delta variant has penetrated Chinese port facilities, Malaysian chip factories, and Bangladeshi textile plants, leading to periodic shutdowns that have spiked container shipping prices and lengthened order backlogs.

Throughout all this, producers seemed to be stuck in quicksand. The past decade has not been shy in signaling to firms that there might be risks to increasingly disaggregated global supply chains. If natural disasters, pandemics, and geopolitical tensions were not enough, now management consultants are piling on. The same consultants who urged offshoring a generation ago are now telling firms to retrench from globalized supply chains. But most firms do not seem terrifically interested in changing their practices. Multinational corporations like Apple have not altered their supply chains in response to political pressure. Whether one looks at business surveys or journalistic accounts, the results are the same: Most U.S. firms do not plan on moving their supply chains away from China.

A world in which the distribution of goods is held up due to constant supply chain disruptions seems less than ideal. What can be done about it?

One thing that would be great is if everyone would acknowledge that a lot of the issues with global value chains right now have to do with demand more than supply.

When the pandemic began, there was an immediate and acute contraction of demand. Producers assumed that this would be the new normal and reduced their output. They were mistaken. The combination of emergency COVID-19 relief and the work-from-home phenomenon led to a resurgence of demand. The affluent class had considerable sums of disposable income. The pandemic made spending on services a less viable option, so instead they spent it on stuff: cars, furniture, home office equipment, gaming systems, house renovations, and so forth. The shortage of semiconductor chips was caused by the unexpected twin rebounds in demand for cars and consumer electronics. As one Federal Reserve analysis explained, "the pause in demand was much shorter and the rebound in demand was much stronger than anticipated." These demand surges surprised suppliers and led to the production bottlenecks that are currently seizing up Pottery Barn orders.

While demand has been stronger than expected, supply in critical sectors coped better than expected. The predicted pandemic breakdowns in supply chains for food and medical supplies proved to be overstated. Surveys of logistical firms last year revealed that the pandemic had minimal effects on their operational capabilities. Even when it came to medicines and personal protective equipment, there were only minor disruptions after the initial shock in March 2020. Claims that the global supply chain in medical products rendered states vulnerable to weaponized interdependence proved to be wildly exaggerated. The pandemic affected service sectors such as tourism far more severely than any manufacturing sector. Indeed, Slate's Jordan Weissmann pointed out recently that "imports were up 5 percent year-over-year in September, and up 17 percent compared with the same time in 2019." This happened despite the decline in air passenger traffic, which restricted yet another means of shipping goods by air. Supply has increased—it's just that demand has surged even more.

The private sector is responding to market signals by ramping up production and ensuring multiple supply lines. Intel, Samsung, and TSMC are all spending tens of billions of dollars to build new chip foundries in the United States. Skyrocketing shipping prices are incentivizing additional construction of new container ships. The Wall Street Journal reports that in the first five months of 2021, there were nearly twice as many orders for new container ships as there were in all of 2019 and 2020 combined. To ensure holiday inventory, large retailers like Walmart and Home Depot have chartered their own container ships. Container shipping rates have already started to decline from September peaks.

But these capital investments designed to boost resilience will take years to kick in. This time lag is one reason private-sector actors have been so slow to invest in resilient supply chains in the past. If disruptions are expected to be temporary, such investments might seem like overreactions. Given the billions of dollars at stake, this sort of risk aversion is unfortunate but understandable.

Long-term investments in resilience make some sense, but short-term investments in robustness make even more sense. Resilience is the ability to adapt in response to permanent shocks to the system. Robustness is the ability to maintain output levels in response to a short-term hit. The most obvious way that firms can enhance their robustness is to warehouse supplies of key components. Car manufacturers, for example, are pledging to ramp up their inventories of critical components to ensure a more reliable production stream.

Yet the auto sector appears to be the exception and not the rule in bolstering inventories. For most firms, increasing reserves of component parts is an expensive proposition. To a corporation, holding inventory is like holding cash: Why sit on an asset that yields no rate of return? Lean manufacturing was popular in the first place because it boosted profits.

Even as semiconductors have grown scarce, chipmakers and chip customers have battled over which firms will shoulder the costs of carrying greater inventory. Under the just-in-time system, the chipmakers had held the inventory. As one semiconductor CEO said earlier this year, the shortage has shifted the balance of power: "If they expect the semiconductor [suppliers] to be the bank, to keep having a big working capital to support them, they can forget it."

Bottlenecks in the global supply chain threaten the macroeconomic and microeconomic health of the United States. On the macro side, supply chain issues are driving fears of inflation; if not brought under control, this could cause the Fed to prematurely raise interest rates. A related problem is consumer panic over rumored shortages. See, for example, the effect of the ransomware attack on Colonial Pipeline—drivers panicked and went to gas stations to top off their tanks, temporarily worsening the problem.

On the micro side, the high price of inventories and shipping imperils market competition. Supply risks privilege larger firms over small and medium enterprises. Multinational corporations have the capacity to make large-scale investments in resilience and robustness. They are also able to use their market power to ensure continued access to scarce container billets in ships; your local bodega, by contrast, is unable to charter an entire container ship. The more stretched the global supply chain, the more sectors that look like monopolies rather than a competitive marketplace.

When it comes to fixes, there has been a surplus of really dumb ideas about what the government could do. Hawley's idea of essentially nationalizing supply chains stands out as the dumbest. Such a move would take well more than the three-year window he proposes to execute. Prices would permanently rise due to new inefficiencies. The opportunities for rent-seeking are legion; every sector would be lobbying Washington that what they produce is "critical." It is also worth remembering that Hawley's go-to policies of protectionism and immigration restriction shoulder much of the blame for the lack of truck drivers that have contributed to delivery delays.

The Biden administration's responses have run the gamut. White House Press Secretary Jen Psaki tried to laugh it all away by reducing the issue to "the tragedy of the treadmill that's delayed." That will not play well with a country used to just-in-time delivery and trying to move past the pandemic. Nor will Biden's proposal to open the port of Los Angeles 24/7 have much of an effect. While ports are currently jammed, there are also bottlenecks in railroad cars and truck drivers—both of which are issues that predated the pandemic. Even if the port gets unstuck, the traffic jam will just migrate to America's railroads and highways.

Looking at manufacturing more generally, some firms have acknowledged that they were unaware of the geographic distribution of their suppliers prior to the pandemic. This is one area where the Biden administration's efforts to collect data on supply chains could be useful.

If the federal government can identify (or even stock) priority components that would affect multiple sectors, those strategic reserves could theoretically bolster the robustness of the U.S. economy. But not if such investments become a stalking horse for protectionism.

All of the evidence of the past year suggests that globalization helps economies recover more quickly from supply chain difficulties than aggressive efforts at homeshoring. This is because most shocks are localized, and access to global value chains facilitates recovery more quickly. Indeed, protectionism is partly to blame for the current mess. As the Cato Institute's Scott Lincicome recently noted, the Jones Act, which mandates use of U.S.-built, crewed, and flagged ships to move cargo from one U.S. port to another, has raised the costs of coastwise shipping, putting even more pressure on truck and train transport.

Unsurprisingly, U.S. producers seeking relief from skyrocketing shipping rates have asked the Biden administration to reduce tariffs. Protectionism isn't the solution to these breakdowns in our supply chains; it's part of the problem.

Vaccine nationalism has hindered global immunization and fueled the development of more dangerous COVID-19 variants, while demand surges have disrupted global supply chains.

In France, 44% of people had faced a drug shortage, causing patient anxiety and worsening symptoms, with French health organisations blaming pharmaceutical companies' lack of transparency for rising drug prices.

Title:

Content: French health groups put forward proposals to limit the damage of worsening drug shortages

Medicines such as cough syrup, lozenges and ointment are seen on a table in an apartment in Berlin, Tuesday, December 20, 2022. Copyright Stephanie Pilick/dpa via AP
Copyright Stephanie Pilick/dpa via AP
By Lauren Chadwick
Share this articleComments
Share this article

Pharmaceutical companies’ lack of transparency leads to rising drug prices and less control over public resources, the group of health organisations say.

ADVERTISEMENT

A group of French organisations have called for more transparency from pharmaceutical companies as drug shortages increase.

In a joint report, 14 civil society organisations outlined their recommendations to solve a “situation that has only worsened” since 2018.

The French medicines regulator signalled 4,925 drug shortages in 2023, compared to 3,761 in 2022 and 2,160 in 2021.

A 2024 survey from France Assos Santé, which represents patients, found that 44 per cent of people in France said they had faced a drug shortage this year.

One of the pharmacy unions in France has even planned a strike at the end of the month over drug shortages and what they say is worsening access to care.

Each health organisation contributed an article with recommendations for dealing with the drug shortages.

The League Against Cancer urged complete transparency on drug shortages and potential substitutions for health professionals.

They also called for monitoring of medicine stocks and their location in the country to guarantee equal access.

The organisation found in a survey published in February that 78 per cent of health professionals in oncology had been faced with a drug shortage.

Drug shortages or delays have led to anxiety among cancer patients, lost time, and worsening symptoms, the organisation said.

France Assos Santé, meanwhile, wrote that an urgent response should not be to support “the industrial sector which bears serious responsibilities” for abandoning the production of less profitable drugs, relocating drug production, and keeping insufficient medicine stocks.

They would like any cost increases justified by production costs or the risk of withdrawing a drug from the market due to it being unprofitable. They called for cost evaluations to be made public.

Their concerns also range from the use of public money to bring drug production to Europe to new government plans to prevent shortages.

Some changes at the EU level criticised

Last year, the European Commission announced several measures to reform the pharmaceutical industry and address critical drug shortages.

The European Parliament went on to adopt a position on pharmaceutical reform last month, that included “incentives for innovation” and an effort to limit overuse of antibiotics.

The non-profit organisation Prescrire, which focuses on information about medicine, wrote in a chapter they contributed to the report that while some of the European Commission’s measures were welcome, others were concerning.

One of the many measures they rejected included the Commission’s proposal to reduce the number of days of scientific evaluation of drugs from 210 to 180, which they said was necessary time rather than an “administrative obstacle”.

While the NGO welcomed some measures such as government drug shortage prevention plans, it said the Commission should allow EU states to require pharmaceutical companies to have safety stocks of medicine and sanction those that do not respect them.

ADVERTISEMENT

French consumer organisation UFC-Que Choisir and the European Consumer Organisation (BEUC) said that they had hoped MEPs would shorten the length of time for “data protection” to allow generic medicines to be marketed more quickly.

Instead, MEPs approved shortening the period to 7.5 years, “which is almost the same duration as the current 8 years [yet] within the framework of the text adopted by Parliament, companies can gain additional months of protection under certain conditions to reach a total of 8.5 years,” UFC-Que Choisir said.

Share this articleComments

You might also like

The FDA declared a nationwide Adderall shortage in 2022 due to manufacturing delays, and manufacturing delays and labor shortages are contributing to the Adderall shortage.

Title:

Content: Nationwide Adderall shortage impacting area pharmacies in the Panhandle

Published: Oct. 19, 2022 at 5:07 PM CDT|Updated: 19 minutes ago

AMARILLO, Texas (KFDA) - The Food and Drug Administration has declared a nationwide Adderall shortage and the Panhandle is feeling the affects.

The FDA blames the shortage on manufacturing delays.

Health experts say a shortage in stimulant medications is actually not a rare occurrence.

“The amount of medication that is produced is limited and regulated by the government, so there have been other years where towards the end of the year in particular, we start to struggle with supply issues. In this case, however, while that does seem to be probably one of the contributing factors, the other issue we’re facing, at least what we’re hearing about it right now, is that the manufacturing delays have been an issue and some of that has been secondary to the labor shortages,” said Dr. Carolyn Lentsch-Parcells, pediatrician and assistant professor at Burnett School of Medicine at TCU.

Martin Tipton Pharmacy is being impacted by this shortage.

“We’re having to order from various manufacturers right now, not our normal manufactures just because we cannot get them from our normal ones,” said Mark Vogler, Martin Tipton Pharmacy.

Fortunately its patients have been able to get their needed medication, just a different brand.

Amarillo Pharmacy is also being impacted, saying the drug has been back ordered for the past two months.

The Amarillo Pharmaceutical Care Center at Texas Tech Physicians is also seeing a back order on one of the strengths of the drug.

“The drug company manufacturers short-acting and extended-release, for example. So, a pharmacist, in this situation, will work collaboratively with the patient’s provider to find an available strength and dosage to meet the patient’s needs until the original strength becomes available again,” said Amarillo Pharmaceutical Care Center at Texas Tech Physicians.

Dr. Lentsch-Parcells acknowledged this may be an uneasy time for those depending on Adderall, especially with the end of the semester and holidays approaching. She encourages you to reach out to your providers.

“There are various strategies that we will sometimes use to help our patients get the best care possible, while we are trying to ride out the shortage, so that might be changing dosage or using dosage forms that are available to replace their typical medication,” said Dr. Lentsch-Parcells

She emphasizes not to make any changes to your medications without speaking to your providers first.

Pharmacy chains, like CVS and Walgreens, both confirm they are seeing intermittent supply issues with the generic form of the drug.

15 cancer drugs are in short supply due to manufacturing and supply chain issues, impacting cancer care locally and nationwide.

Title:

Content: NORTHAMPTON, Mass. (WWLP) – While this shortage of chemotherapy drugs stretches across the country, 22News looks at how the limited amounts of potentially life-saving drugs are impacting cancer care in our area.

It’s a problem, so acute it was recognized by the Biden Administration just last month. The White House noted there’s a shortage of 15 cancer drugs due to manufacturing and supply chain issues.

22News asked Pharmacy Director Michelle Kososki at Mass General Brigham Cooley Dickinson Hospital, to rate the shortage experienced locally on a scale, 5 being a critical shortage and 1 being no shortage at all, “right now I would probably say it is a four. We only have a very small supply of one particular drug.”

Pharmacy Director Michelle Kososki said drug shortages are not uncommon in the healthcare industry however, when faced with potentially life-saving drugs it can get complicated, “Anytime there is a shortage, there’s a risk of not being able to treat patients. Obviously, that is something we want to avoid and we work to the best of our ability with creative solutions to make sure that doesn’t happen.”

Nurse Manager Lisa Martensson at Mass General Care Center at Cooley Dickinson Hospital told 22News, “There’s always the ethical issues of who gets the drug that’s available. It’s supply and demand as you said and looking at what folks had for their disease which ones needed to be treated faster than others based on the aggressiveness of their disease. Those things played in but it was a really difficult decision to sit down and try and decide who would get the drug. We were never in a position where we had to deny anybody.”

Cancer patient Norman Uzdavinis of Whately said he was very concerned when he first heard of the shortage, “I had wondered where in the chemotherapy I would be at, would it have to be delayed for months or years if possible.”

Uzdavinis has not had his medical care compromised but feels for those who have, “I feel for them. I know what I’m going through and that everything is here so it’s perfect for me, but there’s a lot out there that are not as fortunate. I know that.”

“Healthcare providers here were able to mitigate the shortage by using a couple of different tactics. For example, they could switch up a patient’s medication regimen,” Nurse Manager Lisa Martensson said.

“What we did do was use drugs that were in the same classification but not necessarily that specific drug. There are also drug regimens where we could switch around the order to which we gave the drugs so if there was a drug that wasn’t available we are able to do one of the drugs that was available first and do that second drug second. That was able to work out so people didn’t do without and they were able to get what they needed,” Martensson continued.

According to the FDA, the shortage started when one of the major manufacturers of the chemo drug, Accord Healthcare, a company based in India, had to shut down after problems complying with good manufacturing practices were found during an inspection. Now, there is an increased demand from other companies that make these kinds of drugs.

22News contacted some other of the manufacturers of these drugs. Pfizer said they are increasing production by about 40 percent to meet this increased demand.

Local News

Alanna Flood is a reporter who has been a part of the 22News team since 2022. Follow Alanna on X @alannafloodnews and view her bio to see more of her work.

A survey by the American Society of Health System Pharmacists found that one-third of 1,100 hospitals had to alter prescriptions due to drug shortages.

Title:

Content: International
International News
Dependent on foreign raw materials fluctuate, big pharmaceutical companies chase short-term profit loss production
The shortage of ADHD drugs is just the tip of the iceberg of the current drug shortage in the United States. According to the FDA, more than 135 drugs are in short supply, including chemotherapy drugs for cancer.
A survey released by the American Society of Health System Pharmacists (ASHP) in early August showed that one-third of the 1,100 hospitals surveyed had no prescription, delayed or reduced prescriptions due to drug shortages to meet the supply window.
Expert analysis, pharmaceutical companies to pursue short-term profit first business model, so that the production of life-saving drugs and demand out of line, drug shortage problem is difficult to improve.
Experts urge pharmaceutical companies to face social responsibility
Rita Numerof, a medical industry consultant, wrote in Forbes magazine that in order to reduce costs, US pharmaceutical companies have long relied on foreign suppliers such as China, India and Italy to import raw materials for the production of drugs, which is prone to fluctuations in supply. They are looking to develop drugs that are more likely to be used for long-term diseases.
Teva, a manufacturer of ADHD drugs and the world ’ s largest generic drug manufacturer, announced earlier that it would reduce the production of some generic drugs and focus on more profitable products. Rumelove warned that if pharmaceutical companies are unwilling to address their social responsibilities and strengthen supply risk management, public trust in the pharmaceutical industry will continue to weaken, and ultimately public health and safety will pay a heavy price.
Focus on the organization to accelerate the use of new generic drugs to increase production incentives
The American Association for Access to Medicines (AAM) released a report last month, saying that because of restrictions on the supply of generic drugs, the supply price of generic drugs is limited, and the return of investment in new drugs is not high. The situation.
(Forbes / DrugTopics)
(Global Hot Talk)
Related Words: Adderall Drug Shortage Attention Deficit and Hyperactivity Disorder (ADHD)
Previous / Next News

US pharmaceutical companies rely on foreign suppliers like China, India, and Italy for raw materials, making supply prone to fluctuations.

Medication shortages can lead to threats to patient safety, economic implications, an

Title:

Content: Lack of medicines in MOH hospitals and accumulation of indebtedness Repercussions / solutions
3 hours ago
Dr. Naeem Malkawi
The problem of shortage of medicines in Jordanian hospitals requires quick and effective attention and intervention, as providing medicines to patients is one of the foundations of quality health care and one of the most important strategies of the Ministry of Health, however, the shortage of medicines in many hospitals leads to health, economic and social challenges that threaten the quality of health care and patient safety.
The budget of the Ministry of Health of medicines, vaccines, vaccines and medical consumables for this year 2023 was estimated at 103.75 million dinars, where the actual for the past year 2022 was 93.8 million dinars.
The question is, how did the Ministry of Health accumulate such a large indebtedness in the item of medicines to reach 300 million dinars for pharmaceutical companies?
And why last week was the debt of 2019 cleared and deducted estimated at 50% of the debt for that year?
This means that there is still a delay in the payment of dues for companies for the years 2020, 2021 and 2022 in addition to eight months of the current year 2023, and this brings us to a range of reasons and challenges:
1.
The aim of the Ministry of Health was to reduce the bureaucracy of procedures and overcome the complexity of procurement references in hospitals and health directorates in the governorates and not to obtain price and discount preferences, but the results indicate a defect in the management and mechanism of dealing with the strategy of unified and central procurement, despite the margin for hospital administrations to use the power of direct purchase in cases of necessity.
2.
Preparation of sub-budgets for hospitals: Evidence shows that there is a problem in the preparation of sub-budgets for hospitals and the main budget of the Ministry of Health with regard to the item of medicines, which is due to the lack of accurate and sufficient data on the number of patients and hospital needs of medicines, and the lack of accurate forecasting of future needs.
3.
Delays in the review of financial claims and invoices between the Ministry of Health and the hospitals on the one hand and the pharmaceutical companies on the other hand, is one of the most important reasons behind the accumulation of indebtedness, and this negatively affects the liquidity of the pharmaceutical companies and hinders them from providing a sustainable service in adhering to the procedures of supplying medicines according to schedule.
4.
Lack of coordination and communication: There may be a lack of coordination and communication between hospitals, the Ministry of Health and pharmaceutical companies, which complicates the supply and distribution of medicines and increases the chances of delays and the depletion of medicines from hospitals in the absence of an effective policy for stock management and the time required for stock adequacy.
5.
Focusing on the trade names of certain drugs from specific production sources and not adopting the protocol of writing the scientific name for the prescriptions of patients.
6.
One of the reasons that may be major and important at the same time is the funding aspect and the lack of the necessary allocations or use them in other aspects other than medicines to fill a deficit or emergency during the use of budget items due to the scarcity of available liquidity. Medication.
Lack of medication can lead to:
1.
Threat to patient safety: Lack of medication puts sick people at risk, as this can lead to delays in receiving necessary treatment or the unavailability of vital drugs, putting their lives at risk.
2.
Economic Implications: The lack of medicines entails additional economic costs for the health system and patients.
Medical cases may be referred to other medical centers or private hospitals, increasing pressure on other MOH budget items.
3.
Pressure on health care workers: Health care workers are under pressure as a result of dealing with patients affected by drug shortages and repeatedly facing their inquiries and complaints.
4.
Social repercussions:
Increased anxiety and stress: A lack of medication can lead to an increase in anxiety and stress among patients and their families, as they live in uncertainty about the availability of the necessary treatment.
Lack of medication can affect the level of trust in the health system among citizens, who may feel that the system is unable to provide them with adequate health care.
Increased costs and social burdens: Some patients may have to incur additional costs to obtain drugs from other sources outside hospitals, affecting their financial and economic status.
After all this narrative there must be ways to overcome these dilemmas:
1.
Preparation of budgets scientifically and professionally: Hospitals should develop more accurate standards for the preparation of sub-budgets for medicines, through the analysis of previous data, estimation of future needs and other scientific and methodological foundations in the preparation of budgets and commitment to apply them accurately.
2.
Improve coordination and communication between parties: Coordination between the Ministry of Health, hospitals and pharmaceutical companies should be strengthened through the establishment of structured mechanisms for information exchange, review of invoices, and completion of claims, and not delay them.
3.
Implementation of fiscal reforms: The Government and the Ministry of Health should implement fiscal reforms that provide funding to cover this important item and pay dues in a timely manner, reduce bureaucracy in the financial audit process, and proceed with payment procedures within the timetable mechanism agreed in the tender terms.
4.
Achieving social responsibility: The government and pharmaceutical companies should adopt a social responsibility towards patients by providing these drugs and reducing their prices in the market to make them more accessible to patients while relieving part of the pressure and burden on hospitals.
Addressing the problem of drug shortages in government hospitals requires comprehensive cooperation between all concerned parties from government, Ministry of Health, hospitals, drug suppliers and patients.
To provide medicines on a permanent basis and to ensure the provision of high quality health care to the Jordanian patient.


Greenland is rich in rare-earth minerals, in addition to gold, iron-ore, uranium, and other resources.

The island has a favourable legal framework and robust infrastructure, particularly in South Greenland, which has factored into AEX Gold's vision to explore the region.

AEX Gold's subsidiary, Nalunaq Gold Mine, is situated in the Nanortalik Gold belt, Southern Greenland, an area known for its high-grade gold deposits.

The company has acquired an existing Exploitation Licence and holds Exploration Licences at the early exploration stage Vagar and Tartoq properties in South Greenland.

Greenland's rare earth minerals reserves are located throughout the island, with AEX Gold's licences covering a total of 690sqkm in south Greenland.

A Canadian company, Toronto's New Performance Materials, has been granted a license to mine rare metals in Greenland.

The company plans to explore and develop the Surfertog project in Greenland to diversify its global sources of rare earth ore.

The Surfertog Carbonatite complex in Greenland contains mineral deposits rich in neodymium and praseodymium, essential components of rare earth permanent magnets.

Greenland has rare earth minerals reserves located at Kuannersuit, the southern tip of Greenland.

Guanast in southern Greenland is home to the world’s second-largest reserves of rare earths and uranium after China.

The Guanast rare earth reserves account for 10% of the world’s rare earth production.

The climate crisis is causing Greenland's ice to melt at unprecedented rates, creating an opportunity for investors and mining companies looking for rare earth minerals.

Billionaires such as Jeff Bezos, Michael Bloomberg, and Bill Gates are funding large-scale mineral extraction efforts in Greenland.

Kobold Metals is searching for a large nickel and cobalt deposit in Greenland, which could be the largest or second-largest in the world.

The Geological Survey of Denmark and Greenland has identified Greenland as a potential hot spot for coal, copper, gold, rare earth elements, and zinc.

Greenland Minerals & Energy is one of the key manufacturers of Rare Earth Elements.

The global key manufacturers of Rare Earth Elements include Arafura, Alkane Resources, Avalon Rare Metals, China Rare Earth Holdings, Indian Rare Earths, Lynas, Great Western Minerals, Greenland Minerals & Energy and Rare Element Resources.

The government of Greenland revoked the license of a Chinese mining company, Junan, to mine an iron ore deposit near the capital, Nuuk.

China's General Nice took control of the Isua mine in 2015, replacing bankrupt London Mining, in an effort to gain a foothold in the resource-rich Arctic region.

Greenland is expected to start mining rare earths in 2024, with a mining company obtaining permission from the government to do so.

Tanbreez Mining plans to mine rare earths in Greenland, with production potentially starting next year.

The Tanbreez mine is said to contain more than half of the world’s rare earth resources, with 19 million tons of rare earth oxides.

Greenland is rich in rare-earth minerals, in addition to gold, iron-ore, uranium, and other resources.

Title:

Content: AEX Gold aims to invest in Greenland through its new gold mining project

Traditionally known for its fishing and hunting industries, Greenland is fast becoming the next significant area of exploration for mining businesses. The largest island in the world, Greenland remains one of the least populated areas worldwide with 56,000 citizens, and it has sought to attract local and foreign investment across a number of new projects.

The island’s current position remains complex. A sovereign government, it is positioned under the Danish kingdom who provide grants to support its local economy. To further its independence and bolster its economy to create increased tax revenue, Greenland has embraced the exploration of new mining projects as well as utilising all the renewable and local resources it has to offer.

Rich in rare-earth minerals, gold, iron-ore, uranium, in addition to hydro and wind power, Greenland’s favourable legal framework and robust infrastructure, particularly in South Greenland, have factored into AEX Gold’s vision to explore through its Greenlandic subsidiary, Nalunaq Gold Mine, situated in the Nanortalik Gold belt, Southern Greenland.

Acquiring an existing Exploitation Licence in 2015, the company is at the advanced exploration stage of its Nalunaq property, including the previously operating Nalunaq Gold Mine.   It also holds Exploration Licences at the early exploration stage Vagar and Tartoq properties.

Hosting a high-grade NI 43-101 compliant gold resource estimate of 263k oz (inferred) at 18.7 g/t and a number of regional exploration targets, AEX Gold has undertaken three years of exploration at Nalunaq, developing an updated geological model and an extension of the main vein strike length up to 1km.

“The government is very supportive, so it's about having a sound exploration strategy. We are very much focused on that, as we have an asset package that we think we can grow and create a lot of value,” explains Chief Executive Officer, Eldur Olafsson.

Originating from Iceland, Olafsson has gained extensive experience of the local geography. Focusing on mining projects in Greenland since 2012, he has analysed the country’s potential against the backdrop of environmental responsibilities and associated legalities with partner SRK Exploration Services. Through this process, the business has turned its attentions solely towards gold exploration.

“The known gold deposits in Greenland are in an area where the climate is mild and, given our experience, logistics are relatively easy. Gold opportunities are easier to finance than larger base metals projects and our perception was that we could fully fund projects like these through our support here in Iceland and in the UK market,” he explains.

“We started looking for opportunities in the South Greenland Gold Province and became aware of this historically producing mine. We were attracted by the extremely high-grade potential of the resource and the fact that the project had significant infrastructure in place.  We believed there were significant opportunities to materially improve the mining operation that had been run by previous operators.”

Extensive exploration

Throughout the exploration of high-grade resources, Olafsson is proud to remain hands on and is regularly seen on site. By undertaking various technical studies, AEX has gained the ability to comprehensively analyse similar types of assets with potential.  After acquiring the Nalunaq project in 2015 the company has continued to expand its portfolio. Whilst Nalunaq encompasses the required licence to explore and recommence production at the old gold mine, they own the larger Vagar exploration licence, situated a few kilometres to the west of the mine, where AEX believes the ground is prospective for the discovery of further Nalunaq-type deposits.  In addition, they also own the early stage Tartoq Project to the North West of Nalunaq. Each licence area is at a different stage of exploration which supports AEX’s aim of having a continuous pipeline of projects being brought into production.

“We have a total of 690sqkm of licences in south Greenland and we're the only active listed gold company in Greenland. Previous operators undertook very little forward-looking exploration once the mine was in production.  It's a very under-explored region so we intend to recommence production within the next two years at Nalunaq in order to support our exploration in the larger licences in the next 5-10 years,” he says.

“Iceland is a short distance from Greenland, so logistically it’s good for us. Additionally, in Iceland you need to be really self-sufficient, and the same can be said for those in Greenland. We don't have as many people or the multitude of services that you would have in other countries which encourages you to think creatively,” he adds.

Consequently, the company has sought to maximise efficiency whilst keeping costs down, yet all the time adding increased value across its operations.

By acquiring a high-grade deposit, less material is needed to be broken down, lowering AEX Gold’s carbon footprint. Everything taken out of the mine from underground will be processed and shipped out to a different processing facility, or processed on site adhering to the current environmental guidelines. Historically, electricity has been generated through the use of traditional fossil fuels, something which is steadily changing throughout Greenland.

“We're using oil to put in generators or to power mobile mining equipment which is high cost both in monetary and environmental terms.   Greenland currently has five hydroelectric power plants and they are looking at building more in south Greenland,” says Olafsson.

Seeing huge opportunities, he explains that the use of hydropower and wind power would complement AEX Gold’s operations, not only in its existing exploration activities, but with the implementation of an electric mining fleet with electricity being obtained from local renewable resources.

Providing local opportunities

In the future, it will be essential for Greenland to gain further revenue to unlock opportunities and services for its citizens. This is something Olafsson believes that AEX Gold can help with due to its knowledge of Iceland as it has many similarities to Greenland and has been through a period of comparable change.

“Greenland is in a similar position to Iceland not so long ago. Iceland didn't have a high education rate and wasn’t wealthy compared to other European countries, with economic and cultural activities that were very insular. We are now at the highest level of all parameters in terms of education, wealth per family, etc. and this has stemmed from improving the breadth of schooling and creating opportunities for people to grow and develop outside of the traditional areas of agriculture and fisheries.

“Our aim is that the majority of employees will be Greenlandic, but it will take time. Greenland has a large number of people competing for jobs in the fisheries and tourist centres. It is important that Greenlanders are able to access programmes that will allow them to consider other career options. In Iceland we are importing a lot of people to work in different industries in our country because we don't have enough people. This might be the case for Greenlanders as well if the anticipated growth of the Mining Sector materialises but we want to ensure that, where possible, we use local people first before looking elsewhere.

“The Greenlandic Government provides good support for those who seek education.  There are an increasing number of Greenlandic students attending Danish Universities so that now, for example, we are seeing well qualified Greenlandic geologists available for employment.  There has been a Mining School at Sisimiut for the last 10 years which provides local qualified labour who can take advantage of opportunities in the Mining sector.  You need skilled labour and as we own a mine that was in production for 10 years previously, there is a fair bit of local knowledge that we have been able to use during our exploration work and which we are keen to utilise going forward,” he says.

“We are creating revenue for local communities, creating highly skilled jobs, and are providing benefits where local communities can live better lives and grow as individuals. We need to create opportunities for young people.”

Additionally, by working with local businesses as well as those who have been operating in Greenland for some time, AEX has made a conscious effort to hire companies which can support its growth. AEX have therefore acquired a longstanding relationship with Cartwright Drilling, due to the company’s extensive experience in Greenland and subsequent knowledge of the island’s government systems, processes and practices.

Planning to mine high-grade resources using significant infrastructure already in place, AEX Gold holds extensive licences managed by an experienced team. Previous operations produced between 50,000 to 100,000 ounces a year at 15.4 grams/ton produced and this has provided a benchmark for the company, who will utilise this cash flow to explore the wider region in the long-term.

“We have a five-year plan where we want to get into production at Nalunaq and use the cash generated to fund exploration in the wider district.   We envisage investing a significant amount in exploration assets to provide a portfolio of different deposits that we can bring into production. We are creating a company that has a long-term mission in Greenland to build up local know how to support our aim of ramping up to very profitable production across a number of projects,” notes Olafsson.

“It will create a dramatic effect on the local community and hopefully be a springboard for unlocking much larger potential in Greenland. There are plenty of deposits that have been found, but you have to be able to develop them. You can only do that that with support and cooperation from the local people who believe in your vision.”

Share
Share
Author
Executives
Eldur Olafsson

What does Greenland's Tanbreez mine contain?

30% of oxides are highly sought after heavy rare earth metals

The island has a favourable legal framework and robust infrastructure, particularly in South Greenland, which has factored into AEX Gold's vision to explore the region.

Why AEX consider Greenland a favorable mining location?

favorable legal framework
robust infrastructure

AEX Gold's subsidiary, Nalunaq Gold Mine, is situated in the Nanortalik Gold belt, Southern Greenland, an area known for its high-grade gold deposits.

The company has acquired an existing Exploitation Licence and holds Exploration Licences at the early exploration stage Vagar and Tartoq properties in South Greenland.

Aside for Nalunaq, what other exploration license does AEX own?

What other Greenland project is AEX involved in?

Greenland's rare earth minerals reserves are located throughout the island, with AEX Gold's licences covering a total of 690sqkm in south Greenland.

A Canadian company, Toronto's New Performance Materials, has been granted a license to mine rare metals in Greenland.

Title:

Content: A Canadian company has been granted a license to mine rare metals in Greenland.
© AP Photo / David Goldman Greenland ice melt August 3, 2017
Follow us via
Toronto ’ s New Performance Materials, one of the few rare earth metal processors outside China, has obtained an exploration license in Greenland from Hudson Resources in Vancouver (Canada).
Washington - Sputnik.
“Through a special-purpose entity, NEO plans to explore and develop the Surfertog project to further diversify its global sources of rare earth ore and expand the supply chains that feed the company ’ s rare earth ore separation facility in Estonia, ” it said in a statement.
NEO CEO Constantine Karianopoulos told the New York Times that his goal was to reduce the company ’ s exposure to volatile global crude prices.
NEO buys semi-processed raw materials from Russia, the United States and Australia.
"Collects Rare Minerals"...
China enters the world of "space mining" with the launch of the first robot...
A picture.
The Surftog Carbonatite complex contains mineral deposits rich in neodymium and praseodymium, which are essential components of the rare earth permanent magnet used in electric vehicles, wind turbines, high-efficiency electric motors and pumps that help reduce greenhouse gas emissions.
NEO also plans to build a new permanent magnet manufacturing plant in Estonia to supply European manufacturers of electric and hybrid vehicles, wind turbines, and energy-efficient electric motors and pumps, the statement said.
News Ticker
0.
To participate in the discussion
Sign in or Register
loader
Conversations
Заголовок открываемого материала

What Canadian rare earths processing company obtained an exploration permit in Greenland?

The company plans to explore and develop the Surfertog project in Greenland to diversify its global sources of rare earth ore.

The Surfertog Carbonatite complex in Greenland contains mineral deposits rich in neodymium and praseodymium, essential components of rare earth permanent magnets.

Greenland has rare earth minerals reserves located at Kuannersuit, the southern tip of Greenland.

Title:

Content: Greenland ban on uranium mining prevents Chinese companies from expanding rare earths
November 13, 2021 17: 33
Eastern Network Television
More News Clips
As part of its Arctic strategy, China has supported the mining of rare earths in Greenland by Australia ’ s Greenland Minerals, a Chinese-owned subsidiary of Shenghe Resources, through the Belt and Road Initiative.
However, Greenland ’ s parliament passed a new law banning uranium mining and halting the development of rare earth deposits at Kuannersuit, the southern tip of Greenland.
China's rare earth mining accounts for more than 70% of the global mining volume, and China's rare earth magnetic processing volume accounts for 90% of the global processing volume.
Sungho Resources, one of the world ’ s largest producers of rare earth materials, acquired a 12.5% stake in Greenland Minerals in 2016, making it the largest shareholder in the latter.
Guanast in southern Greenland is home to the world ’ s second-largest reserves of rare earths and uranium after China, accounting for 10% of the world ’ s rare earth production.
Since former US President Donald Trump proposed the idea of buying Greenland in 2019, the rich rare earth resources of Guanaster in southern Greenland have attracted attention.
Greenland ’ s local parliament was elected early on April 6. In the end, the pro-environmental left-wing Inuit Ataqatigiit party won the election, and its leader, Mute Egede, became the new prime minister.
He declared that he would do everything in his power to stop the Guanast Rare Earth Mine project.
In response, Greenland ’ s parliament has passed a new bill aimed at banning exploration of uranium deposits, as well as other radioactive deposits such as thorium, and halting the development of rare earth deposits at the southern tip of Greenland.

Which Greenland rare earth deposits has its Parliament prohibited from developing?

Guanast in southern Greenland is home to the world’s second-largest reserves of rare earths and uranium after China.

The Guanast rare earth reserves account for 10% of the world’s rare earth production.

The climate crisis is causing Greenland's ice to melt at unprecedented rates, creating an opportunity for investors and mining companies looking for rare earth minerals.

Title:

Content: Advertisement
Economics.
A race between financiers around the world to search for this substance in Greenland.
Interesting details!
10-08-2022 | 00: 49
A-
A +
photos 0
A +
A-
CNN reports that some of the world ’ s wealthiest people are funding large treasure hunts using helicopters and signal transmitters on Greenland ’ s west coast.
The climate crisis is causing Greenland ’ s ice to melt at unprecedented rates, ironically creating an opportunity for investors and mining companies looking for a treasure trove of important minerals capable of powering clean energy transitions.
Advertisement
Search for minerals in Greenland
Many billionaires, including Jeff Bezos, Michael Bloomberg and Bill Gates, are betting that what lies beneath the surface of the hills and valleys of Disco Island and Greenland ’ s Noswak Peninsula are important enough minerals to power millions of electric vehicles.
Speaking to CNN, Kobold Metals CEO Kurt House said: “We are looking for a deposition that will be the largest or second largest nickel and cobalt deposition in the world. ”
The disappearance of Arctic ice – both on land and in the ocean – highlights a unique dichotomy: Greenland is the zero point for the effects of climate change, but it could also be the zero point for the search for the minerals needed to provide solutions to this crisis.
For their part, representatives of Kobold Metals, a California-based mineral exploration company, said the billionaires ’ club is supporting the company financially.
Bezos, Gates and Bloomberg did not respond to requests from CNN for comment on the news, and Kobold Metals is partnering with Bluejay Mining to find precious and rare metals in Greenland, which are essential for building the electric vehicles and huge batteries needed to store renewable energy.
The Geological Survey of Denmark and Greenland said Greenland could be a hot spot for coal, copper, gold, rare earth elements and zinc.
The Greenland government has conducted several assessments on ice-free land and is aware of the country ’ s “ability to diversify the national economy through mineral extraction, ” the agency said.
(Arabic Post)
Go ahead.
Advertisement
Our news via your email
SIGN UP
Softimpact
All rights reserved © Lebanon24
All rights reserved © Lebanon24
Softimpact

Billionaires such as Jeff Bezos, Michael Bloomberg, and Bill Gates are funding large-scale mineral extraction efforts in Greenland.

Kobold Metals is searching for a large nickel and cobalt deposit in Greenland, which could be the largest or second-largest in the world.

The Geological Survey of Denmark and Greenland has identified Greenland as a potential hot spot for coal, copper, gold, rare earth elements, and zinc.

Greenland Minerals & Energy is one of the key manufacturers of Rare Earth Elements.

Title:

Content: Uncategorized

Rare Earth Elements Market, Global Outlook and Forecast 2022-2028

Rare Earth Element is one of a set of seventeen chemical elements in the periodic table, specifically the fifteen lanthanides, as well as scandium and yttrium. Scandium and yttrium are considered rare-earth elements because they tend to occur in the same ore deposits as the lanthanides and exhibit similar chemical properties.
This report contains market size and forecasts of Rare Earth Elements in global, including the following market information:
Global Rare Earth Elements Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Rare Earth Elements Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Rare Earth Elements companies in 2021 (%)
The global Rare Earth Elements market was valued at 2659.4 million in 2021 and is projected to reach US$ 3906.3 million by 2028, at a CAGR of 5.6% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Cerium Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Rare Earth Elements include Arafura, Alkane Resources, Avalon Rare Metals, China Rare Earth Holdings, Indian Rare Earths, Lynas, Great Western Minerals, Greenland Minerals & Energy and Rare Element Resources, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Rare Earth Elements manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Rare Earth Elements Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Rare Earth Elements Market Segment Percentages, by Type, 2021 (%)
Cerium
Dysprosium
Erbium
Europium
Gadolinium
Holmium
Lanthanum
Lutetium
Neodymium
Praseodymium
Global Rare Earth Elements Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Rare Earth Elements Market Segment Percentages, by Application, 2021 (%)
Magnets
Catalysts
Metallurgy
Polishing
Glass
Phosphors
Ceramics
Other
Global Rare Earth Elements Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Rare Earth Elements Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Rare Earth Elements revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Rare Earth Elements revenues share in global market, 2021 (%)
Key companies Rare Earth Elements sales in global market, 2017-2022 (Estimated), (MT)
Key companies Rare Earth Elements sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Arafura
Alkane Resources
Avalon Rare Metals
China Rare Earth Holdings
Indian Rare Earths
Lynas
Great Western Minerals
Greenland Minerals & Energy
Rare Element Resources
Molycorp
Inner Mongolia Baotou Steel Rare Earth Hi-Tech
Frontier Rare Earths

Download FREE Sample of this Report @ https://www.statsmarketresearch.com/download-free-sample/7131409/global-rare-earth-elements-forecast-2022-2028-651

Table of content

1 Introduction to Research & Analysis Reports
1.1 Rare Earth Elements Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Rare Earth Elements Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Rare Earth Elements Overall Market Size
2.1 Global Rare Earth Elements Market Size: 2021 VS 2028
2.2 Global Rare Earth Elements Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Rare Earth Elements Sales: 2017-2028
3 Company Landscape
3.1 Top Rare Earth Elements Players in Global Market
3.2 Top Global Rare Earth Elements Companies Ranked by Revenue
3.3 Global Rare Earth Elements Revenue by Companies
3.4 Global Rare Earth Elements Sales by Companies
3.5 Global Rare Earth Elements Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Rare Earth Elements Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Rare Earth Elements Product Type
3.8 Tier 1, Tier 2 and Tier 3 Rare Earth Elements Players in Global Market
3.8.1 List of Global Tier 1 Rare Earth Elements Companies
3.8.2 List of Global Tier 2 and Tier 3 Rare Earth Elements Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Rare Earth El

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170 / +91 8087042414

Related Articles

Back to top button

What is one of the global key REE manufacturers?

The global key manufacturers of Rare Earth Elements include Arafura, Alkane Resources, Avalon Rare Metals, China Rare Earth Holdings, Indian Rare Earths, Lynas, Great Western Minerals, Greenland Minerals & Energy and Rare Element Resources.

What is one of the global key REE manufacturers?

The government of Greenland revoked the license of a Chinese mining company, Junan, to mine an iron ore deposit near the capital, Nuuk.

Title:

Content: The government of Greenland, which is located in the Arctic, said on Monday it had revoked the license of a Chinese mining company to mine an iron ore deposit near the capital, Nuuk.
The move has dealt a blow to efforts by Chinese companies to gain a foothold in the resource-rich Arctic region.
China ’ s General Nice took control of the Isua mine in 2015, replacing bankrupt London Mining.
Junan became the first Chinese company to acquire mining rights in Greenland.
Greenland is an autonomous region of Denmark and is rich in minerals.
As a result of the warming climate, waterways have been opened, allowing the resources of the Arctic Island to be developed and utilized.
The Greenland government pointed out that the mine was idle and Junan did not pay the agreed guarantee and therefore withdrew its license.
Once Junan returns the license, Greenland will re-offer it to interested companies.
At present, the government of Greenland has asked Junan to return all the geological data, pay the remaining 1.5 million Danish kroner (about $226,000) of the deposit, and clean up the mine.
The London mine, which was granted mining rights in 2013, initially planned to employ 2,000 Chinese workers to mine, with a goal of supplying about 15 million tonnes of iron ore to China each year.
Greenland banned uranium mining this year, blocking mining in the Kuannersuit region, one of the world ’ s largest rare earth mines and partly owned by a Chinese company.
Junan tried to buy an abandoned naval base in Greenland from Denmark in 2016, but sources told Reuters at the time that the Danish authorities had rejected the proposal for security reasons.
# Greenland # Junan # Mining # China # Mining

What has Greenland done to undermine Chinese efforts to establish a foothold in the Arctic region?

China's General Nice took control of the Isua mine in 2015, replacing bankrupt London Mining, in an effort to gain a foothold in the resource-rich Arctic region.

What countries are invested in Greenland Minerals corp?

Greenland is expected to start mining rare earths in 2024, with a mining company obtaining permission from the government to do so.

Title:

Content: Greenland to mine rare earths in 2024 | Economic Horizontal | DW | 30.07.2023
1.
Inhalt
2.
Navigation
3.
Weitere Inhalte
4.
Metanavigation
5.
Suche
6.
Choose from 30 Languages
Advertisement
Economic stratification
Greenland to mine rare earths in 2024
According to the German "Economic Weekly" reported that a mining company has obtained permission from the Greenland government to mine rare earths on the island.
The company said production could begin next year.
Tanbreez Mining, a mining company, plans to mine rare earths in Greenland next year, according to the Economic Weekly.
“We can start production next year, ” said Greg Barnes, a geologist and owner of the company. Greenland ’ s deputy minister for minerals confirmed to the journal that a mining licence had been issued.
Barnes said the Tanbreez mine "contains more than half of the world's rare earth resources" and has 19 million tons of rare earth oxides.
Of these, 30% are highly favored heavy rare earth elements.
Rare earth contains a total of 17 kinds of metal elements, the properties of each metal are different.
Each metal has a unique industrial value.
Some of them are irreplaceable.
They are used, for example, in the manufacture of electric vehicles or wind turbines.
Last year, about two-thirds of Germany ’ s rare earths came from China. Mining such as rare earths is difficult and often harmful to the environment, as rare earths are often associated with iron ore, and the chemical process of refining often requires the use of acidic substances.
What is Rare Earth?
Barnes, owner of Tanbreez Mining, told Economic Weekly that to start mining for rare earths in Greenland, a factory would be needed to separate rare earths from heterosexual rocks.
Currently there are only such factories in Russia and China.
But one such plant will be built in the United States in the coming months.
There are also plans to build a factory in Europe.
Thanks to technological advances, the equipment that separates rare earths currently costs only $40 million.
According to Barnes, China paid 1.7 billion U.S. dollars for the equipment 13 years ago.
In January, Swedish state-owned mining company LKAB announced the discovery of Europe ’ s largest rare earth deposit to date.
But the company said it would take 10-15 years for the rare earth mine, located in Kiruna in northern Sweden, to be available to the market.
EU Plans to Diversify Rare Earth Supply Chain
(Agence France-Presse, Economic Weekly)
© 2023 Deutsche Welle Copyright Notice: All content in this article is protected by copyright law and may not be used without special permission from Deutsche Welle.
Any misconduct will lead to recovery and criminal prosecution.
DW.COM

Tanbreez Mining plans to mine rare earths in Greenland, with production potentially starting next year.

What company has obtained permission to extract Greenland's rare earths?

The Tanbreez mine is said to contain more than half of the world’s rare earth resources, with 19 million tons of rare earth oxides.

What does Greenland's Tanbreez mine contain?

19 million tons of rare earth oxides
over half of rare earth resources